Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.54 |
| ▸ | HRH1 | P35367 | 9/20 | 0.51 |
| ▸ | HRH2 | P25021 | 7/20 | 0.51 |
| ▸ | DRD3 | P35462 | 4/20 | 0.48 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.47 |
| ▸ | ATF4 | P18848 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 2/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.46 |
| ▸ | HTR2A | P28223 | 2/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.46 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.46 |
| ▸ | DRD1 | P21728 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL491704 | 0.93 | HRH3 (0.64) | HRH3HRH1HRH2EGLN2 | |
| SCHEMBL7246784 | 0.91 | HRH3 (0.63) | HRH3HRH1HRH2EGLN2 | |
| SCHEMBL3564647 | 0.88 | MEN1 (0.48) | HRH3HRH1HRH2SIGMAR1 | |
| SCHEMBL7244494 | 0.87 | HRH3 (0.66) | HRH3HRH1HRH2EGLN2 | |
| SCHEMBL3558558 | 0.84 | SIGMAR1 (0.56) | HRH3HRH1HRH2SIGMAR1 | |
| SCHEMBL3559203 | 0.84 | SIGMAR1 (0.56) | HRH3HRH1HRH2SIGMAR1 | |
| SCHEMBL7251887 | 0.84 | HRH2 (0.52) | HRH3HRH1HRH2 | |
| SCHEMBL7251662 | 0.84 | HRH2 (0.60) | HRH3HRH1HRH2 | |
| SCHEMBL7786637 | 0.81 | HRH2 (0.45) | HRH3HRH1HRH2ATF4ALDH1A1 | |
| SCHEMBL7246082 | 0.81 | GPR119 (0.51) | HRH3HRH1HRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1481966-B1 | NOVEL ARYLAMIDINE DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2011-07-20 | — | — | EP | disclosed |
| US-7291617-B2 | Arylamidine derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-11-06 | — | — | US | disclosed |
| US-7291617-B2 | Arylamidine derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-11-06 | — | — | US | disclosed |
| US-20050113424-A1 | Novel arylamidine derivative or salt thereof | TOYAMA CHEMICAL CO., LTD (JP) | 2005-05-26 | — | — | US | disclosed |
| EP-1481966-A1 | NOVEL ARYLAMIDINE DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2004-12-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113424-A1 | Novel arylamidine derivative or salt thereof | SLC7A1, NAT1, NACA | HRH3 395/4885HRH1 386/4885HRH2 284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.